Home / Stocks / Alkem Laboratories Ltd.
ALKEM

Alkem Laboratories Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹5,145.0

Change

-77.5 (-1.48%)

Open

₹5,220.0

Prev. Close

₹5,222.5

Day High

₹5,233.5

Day Low

₹5,115.0

Volume Analysis

Traded

243,631

Delivered

100,271

Delivery %

41.16%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (20.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (32.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹5,332.5 ₹5,283.0 ₹5,214.0 ₹5,164.5 ₹5,095.5 ₹5,046.0 ₹4,977.0
Fibonacci ₹5,283.0 ₹5,237.73 ₹5,209.77 ₹5,164.5 ₹5,119.23 ₹5,091.27 ₹5,046.0
Camarilla ₹5,177.59 ₹5,166.73 ₹5,155.86 ₹5,164.5 ₹5,134.14 ₹5,123.28 ₹5,112.41

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-5.83%

1 Week

-2.96%

1 Month

+2.59%

3 Months

-4.72%

6 Months

-4.8%

1 Year

-9.74%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹2,320.35

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

13.27%

Net margin 13.38% × asset turnover 0.64x × equity multiplier 1.55x

Company Overview

Sector

Healthcare

Market Cap

₹61,875 Cr

P/E (TTM)

28.6

ROE

18.9%

Book Value

₹1,243.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Alkem Laboratories Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Momentum (32/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%); promoter holding is falling. Strong 3-year EPS growth (32.7%).

TopFund Score — Fundamentals Quality

69/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

58

Valuation

48

Cash Flow

58

Corporate Governance

76

Momentum

32

Institutional Ownership

74

Business Quality

81

Risk & Volatility

70

Liquidity

80

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 26.3%
  • −The company has delivered a poor sales growth of 10.7% over past five years.
  • −Promoter holding has decreased over last 3 years: -7.04%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Please find attached herewith intimation for a copy of newspaper publication.

Q2 and H1FY27 earnings conference call audio recording uploaded on company website.

Alkem Laboratories appoints Mr. Gopal Kothari as CFO and KMP effective 2 December 2026.

Pl find enclosed press release and analyst presentation on Q2 and H1FY27 earnings and business updates of the Company

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 3,440 3,324 2,936 3,032 3,415 3,374 3,144 3,371 4,001 3,737 3,603 3,740 4,552
Expenses + 2,693 2,616 2,534 2,423 2,662 2,615 2,752 2,632 3,080 2,909 3,086 2,974 3,527
Operating Profit 747 708 402 609 753 759 391 739 921 828 517 766 1,025
OPM % 22.0% 21.0% 14.0% 20.0% 22.0% 23.0% 12.0% 22.0% 23.0% 22.0% 14.0% 20.0% 23.0%
Other Income + 6 42 76 120 134 93 146 149 104 90 65 153 169
Interest 30 25 27 29 28 36 28 30 35 42 54 47 58
Depreciation 74 70 83 80 79 85 112 88 94 95 106 100 137
Profit before tax 648 655 367 619 780 731 396 771 896 781 423 772 1,000
Tax % 5.0% 8.0% 17.0% 11.0% 10.0% 12.0% 18.0% 13.0% 13.0% 16.0% 40.0% 32.0% 33.0%
Net Profit + 615 604 304 550 702 641 322 668 779 653 251 521 667
EPS in Rs 52 50 25 46 58 52 26 56 64 53 20 43 56
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 12 9 1 2 -1 2 7 11 17 11 15 11 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,674 4,905 5,688 6,401 7,357 8,344 8,865 10,634 11,599 12,668 12,965 14,712 15,632
Expenses + 3,248 4,038 4,687 5,392 6,237 6,868 6,920 8,580 9,977 10,419 10,452 11,706 12,496
Operating Profit 427 866 1,001 1,009 1,120 1,476 1,945 2,054 1,622 2,249 2,512 3,007 3,137
OPM % 12.0% 18.0% 18.0% 16.0% 15.0% 18.0% 22.0% 19.0% 14.0% 18.0% 19.0% 20.0% 20.0%
Other Income + 176 227 110 115 82 102 230 146 101 186 494 407 477
Interest 81 71 45 55 55 65 59 52 107 112 122 161 200
Depreciation 71 93 101 143 193 253 275 304 310 299 357 382 438
Profit before tax 451 928 965 926 955 1,260 1,842 1,844 1,305 2,023 2,527 2,871 2,976
Tax % 13.0% 19.0% 6.0% 31.0% 19.0% 9.0% 12.0% 9.0% 23.0% 10.0% 12.0% 18.0% —
Net Profit + 392 752 905 638 774 1,149 1,618 1,680 1,007 1,811 2,215 2,351 2,092
EPS in Rs 33 62 75 53 64 94 133 138 82 150 181 193 173
Dividend Payout % 12.0% 20.0% 20.0% 25.0% 25.0% 27.0% 23.0% 25.0% 61.0% 27.0% 25.0% 28.0% —
Sales growth 18 33 16 13 15 13 6 20 9 9 2 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 2,975 3,668 4,444 4,840 5,415 6,137 7,353 8,614 9,021 10,288 11,961 13,796 14,841
Borrowings + 1,306 658 659 998 944 1,616 1,707 2,668 1,397 1,418 1,381 2,047 2,310
Other Liabilities + 986 1,184 1,440 1,803 1,824 2,169 2,435 2,763 3,315 3,844 4,325 4,991 5,885
Total Liabilities 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757 15,575 17,691 20,858 23,060
Fixed Assets + 1,374 1,450 1,797 2,284 2,530 2,908 2,793 2,902 2,683 2,873 2,852 3,871 5,878
CWIP 111 172 299 381 493 363 393 339 323 159 548 282 161
Investments 481 509 553 444 324 261 333 371 622 484 1,846 1,869 2,073
Other Assets + 3,325 3,403 3,918 4,555 4,861 6,413 8,000 10,457 10,129 12,060 12,445 14,836 14,948
Total Assets 5,291 5,534 6,568 7,664 8,208 9,946 11,519 14,069 13,757 15,575 17,691 20,858 23,060
Equity Capital 24 24 24 24 24 24 24 24 24 24 24 24 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 325 726 471 266 780 585 1,265 1,111 1,682 1,948 1,913 1,963
Cash from Investing Activity + -235 205 -294 -351 -318 -737 -995 -1,433 120 -1,011 -1,288 -1,682
Cash from Financing Activity + -52 -927 -138 85 -379 79 -272 380 -1,761 -1,145 -811 -503
Net Cash Flow 39 3 40 0 82 -73 -2 58 42 -207 -186 -222
Free Cash Flow 190 472 -163 -411 253 237 1,116 783 1,453 1,761 1,278 1,476
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101 107 73 47 92 59 86 73 121 105 96 86

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 56.74% → 49.7%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 18.86% 18.51% 16.37% 16.12% 16.19% 16.05% 16.05% 17.39% 17.3% 17.25% 17.25% 17.14%
Promoters 56.74% 56.74% 56.38% 55.66% 55.66% 55.13% 53.04% 51.2% 51.2% 51.2% 49.7% 49.7%
FII 8.49% 9.11% 8.69% 9.02% 10.14% 9.4% 9.11% 9.47% 9.97% 10.15% 10.42% 10.32%
DII 15.91% 15.63% 18.56% 19.21% 18.01% 19.42% 21.8% 21.93% 21.54% 21.39% 22.64% 22.83%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Alkem Laboratories Ltd. (this stock) 61,875 28.6 4.16 18.9%
Fortis Healthcare Ltd 61,047 56.9 5.81 11.2%
Aster Dm Quality Care Ltd 63,907 122.0 8.2 11.3%
Biocon Limited. 58,962 86.5 1.69 1.4%
Gland Pharma Limited 53,710 42.9 5.01 10.7%
Anthem Biosciences Ltd 51,355 81.4 15.65 22.3%
Glenmark Pharmaceuticals 73,937 36.5 6.59 23.6%

Which Mutual Funds Hold Alkem Laboratories Ltd.?

Frequently Asked Questions about Alkem Laboratories Ltd.

Community Sentiment

What are other investors saying about Alkem Laboratories Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.